DaVita stock trades around $180 as Q2 2026 growth and kidney-care partnership shape expectations
Published on 09/01/2026 at 09:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
DaVita Inc. (US23918K1088) stock is trading close to $180 in late August 2026, with investors weighing solid second-quarter 2026 growth against a still-cautious consensus view on the kidney-care provider's longer-term prospects.
The company has reported improved revenue and earnings for the second quarter of 2026 and highlighted operational gains such as higher revenue per treatment and more U.S. dialysis treatments per day, while also announcing a new value-based care agreement aimed at Medicare Advantage members with advanced chronic kidney disease.
Against that backdrop, DaVita's shares have recently opened at $180.72 on the New York Stock Exchange, giving the company a market value of $11.53 billion and placing the current price in the lower half of a 52-week range that stretches from $101.00 to $247.49.
Q2 2026 earnings show revenue and earnings growth
In its second-quarter 2026 results, DaVita reported that both its top and bottom lines increased versus the prior-year period, supported by higher revenue per dialysis treatment and a sequential increase in total U.S. dialysis treatments per day.
Financial commentary on the quarter notes that the company saw solid revenues from multiple sources and an uptick in normalized non-acquired treatment volume, indicating that growth was not driven only by acquisitions but also by underlying demand for its kidney-care services.
On the earnings call covering the quarter, management pointed to plans for deploying expanded hemodialysis across the company's network once there is an adequate supply of newly approved dialyzers, suggesting that DaVita intends to leverage recent regulatory approvals to enhance patient care and potentially improve efficiency.
From an analyst-consensus perspective, projections for the full year 2026 point to revenue growth of 4.7 percent and earnings growth of 35.2 percent, signaling expectations of a substantial recovery in profit relative to prior periods and a more modest but steady increase in sales.
Those projections also translate into an earnings yield of 8.2 percent compared with 4.7 percent for the broader healthcare industry group, indicating that, at current valuation levels, DaVita offers a higher ratio of earnings to share price than the average peer in its sector.
Analyst consensus and valuation context
Consensus data show that DaVita carries a Hold rating, with analysts projecting that 2026 revenue will rise by 4.7 percent while earnings expand by 35.2 percent, a combination that points toward margin improvement and efficiency gains if the forecasts are realized.
That earnings growth expectation, together with the 8.2 percent earnings yield versus a 4.7 percent figure for the industry, suggests that DaVita is currently valued at a discount to peers when measured on an earnings basis, even after the recent share-price gains.
At the same time, the company's current opening price of $180.72 places the stock well below its 52-week high of $247.49 and above its 52-week low of $101.00, a positioning that reflects both the recovery from lower levels and lingering caution among investors who are not yet willing to re-rate the shares back toward their peak.
Looking at recent market activity, DaVita shares opened at $180.72 in a recent session, with the price level consistent across multiple market-data snapshots; this implies that the stock has been stable around that mark rather than experiencing sharp day-to-day swings.
For longer-term holders, performance data indicate that an investment made five years ago would have grown substantially by late August 2026, with the closing price on August 28, 2026, recorded at $180.68 and the value of that hypothetical investment now standing at $138.17 on a unit basis in the referenced calculation.
Kidney-care partnership and strategic initiatives
Beyond quarterly numbers, DaVita has recently announced a value-based care agreement with a major Medicare Advantage plan sponsor, focused on members with chronic kidney disease in stages 3B through 5.
This partnership aims to deliver comprehensive, coordinated care to those patients, aligning incentives so that DaVita is rewarded for improving outcomes and managing costs rather than simply providing more dialysis sessions, a shift that fits broader trends in U.S. healthcare policy.
Such value-based arrangements can be particularly important in advanced chronic kidney disease, where timely intervention and integrated management may delay progression to end-stage renal disease, reduce hospitalizations, and enhance quality of life.
DaVita's management has also emphasized plans to roll out expanded hemodialysis across its network as soon as supply of newly approved dialyzers is sufficient, a move that could provide patients with more flexible treatment options and potentially improve clinical results.
These operational initiatives complement the financial picture, as higher revenue per treatment and increased treatment volumes in the United States offer levers for earnings growth while the company navigates reimbursement dynamics and regulatory changes.
Ownership changes and institutional interest
Recent filings and market commentary highlight that institutional investors have been adjusting their positions in DaVita, with some firms establishing new stakes and others building existing holdings.
The presence of institutional activity at current price levels around $180.72 suggests that professional investors see a balance between upside potential, given the earnings growth outlook, and the risks inherent in a highly regulated healthcare business.
Because DaVita is a constituent of the S&P 500 index, changes in its share price also feed through to broader market benchmarks and to the performance of index-tracking funds that include the stock.
Consensus data point to a price target of $221.75, implying that, if realized, the shares would need to rise from the current opening level of $180.72, a gap that illustrates the room analysts see for rerating if the company continues to execute on its plans and meets or exceeds earnings expectations.
That implied upside, however, is framed within a Hold rating rather than a more aggressive Buy, reinforcing the notion that analysts regard DaVita as balanced between opportunity and risk at present.
DaVita's kidney-care services
DaVita Inc. is best known for operating outpatient dialysis centers that provide treatment to patients with chronic kidney failure and end-stage renal disease.
The company manages facilities where patients receive hemodialysis several times per week, using specialized machines and dialyzers to filter waste and excess fluid from the blood when the kidneys can no longer perform those functions adequately.
DaVita also offers related services, including patient education, support for home-based dialysis modalities, and coordination with nephrologists and other healthcare providers to ensure that care plans are tailored to individual clinical needs.
In some markets, the company participates in integrated-care programs that encompass earlier stages of kidney disease, aiming to slow progression through careful management of blood pressure, diabetes, and other contributing conditions.
By combining clinical expertise with scale in managing dialysis operations, DaVita seeks to deliver both high-quality care and efficiencies that can support sustainable reimbursement levels under public and private insurance programs.
DaVita stock and recent price level
DaVita stock is listed on the New York Stock Exchange under the ticker DVA, and recent data show the shares opening at $180.72 with a market capitalization of $11.53 billion as of late August 2026.
At that opening price, the stock trades within a 52-week range of $101.00 to $247.49, closer to the midpoint than to the extremes, which indicates that while the shares have recovered meaningfully from their lows, they remain below the highs reached earlier in the period.
The positioning of $180.72 relative to the 52-week high of $247.49 underscores that the stock would need to gain more than $60 to revisit its peak, a gap that frames the potential upside if earnings and cash flow trends continue to strengthen.
For investors, the combination of a higher earnings yield than the broader healthcare industry, a consensus expectation of 35.2 percent earnings growth in 2026, and a current price below the 52-week high creates a nuanced picture: DaVita shares offer a relatively attractive earnings-based valuation but still carry exposure to reimbursement risk and operational execution in a complex clinical environment.
Read more
More on DaVita stock
DaVita dialysis services as a core product
A representative product within DaVita's business is its in-center hemodialysis service, which provides lifesaving treatment to patients whose kidneys can no longer adequately filter blood.
During a typical session, blood is drawn from the patient, passed through a dialyzer that removes waste products and excess fluid, and then returned to the body, a cycle that is repeated over several hours and usually performed multiple times each week.
DaVita's centers are staffed by nurses, technicians, and other professionals who monitor vital signs, manage machine settings, and ensure that treatments adhere to clinical protocols designed to minimize complications.
The company invests in training and standardized procedures across its network to maintain consistent quality, while also working with nephrologists to individualize treatment plans based on laboratory values, comorbidities, and patient preferences.
As technology evolves, including improvements in dialyzers and monitoring equipment, DaVita seeks to incorporate those advances into its service offerings, which can enhance patient comfort, reduce side effects, and potentially improve long-term outcomes.
Price level and investor takeaway
DaVita stock's recent opening price of $180.72, paired with a market cap of $11.53 billion and a 52-week range from $101.00 to $247.49, provides investors with clear reference points for evaluating the shares as of late August 2026.
Placed against the backdrop of expected 4.7 percent revenue growth and 35.2 percent earnings growth in 2026, those market figures highlight a company that is generating improved financial performance yet still trades at a valuation that offers a higher earnings yield than the broader healthcare industry, inviting ongoing analysis of how future quarters and strategic initiatives will influence the stock.
Fact box
Company: DaVita Inc.
ISIN: US23918K1088
Ticker: DVA
Exchange: NYSE
Price (as of August 31, 2026, 9:30 a.m. ET): $180.72 USD
Market cap: $11.53 billion (as of August 31, 2026)
Sector / Industry: Health Care / Health Care Providers & Services
Index membership: S&P 500
